Bangabandhu Sheikh Mujib Medical College is getting ready for the human trial of a COVID-19 vaccine developed by French pharmaceutical firm Sanofi.
BSMMU has submitted its proposal to the Bangladesh Medical Analysis Council for approval of the trial, officers mentioned.
The anticipated starting of the phase-Three trial is but to be finalised, however about 500 volunteers are prone to take part within the trial, they mentioned.
‘We’re in talks with Sanofi for the COVID-19 vaccine trial at our facility,’ BSMMU vice-chancellor Kanak Kanti Barua on Friday informed New Age.
‘Once the BMRC gives us the approval we will finalise the agreement with Sanofi,’ he mentioned.
Sanofi is growing two COVID-19 vaccines — one in medical trial stage and the opposite in pre-clinical stage, in response to the World Well being Organisation’s draft checklist of vaccine candidates.
Sanofi is now conducting their phase-1 and phase-2 medical trials within the USA.
The vaccine candidate, developed by a partnership between Sanofi and GSK, makes use of the identical recombinant protein-based expertise as one in all Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant expertise, in response to a Sanofi assertion.
The businesses anticipate the primary outcomes of the phase-1 and phase-2 trials early December which is able to help the initiation of the phase-Three trial the identical month, it mentioned.
Vaccines usually require years of analysis and testing earlier than reaching the clinic, however scientists are racing to provide a secure and efficient coronavirus vaccine by subsequent yr.
Researchers are testing 54 vaccines in medical trials on people, and a minimum of 87 pre-clinical vaccines are below energetic investigation in animals, in response to the Coronavirus Vaccine Tracker of New York Occasions.
Earlier, Chinese language agency Sinovac, in partnership with ICDDR,B, took approval for phase-Three trial of the Sinovac-developed COVID-19 vaccine in Bangladesh.
However the trial course of halted after Sinovac sought co-funding from Bangladesh for the trial.
Native agency Globe Biotech can also be growing three COVID-19 vaccines.
The vaccines are in pre-clinical stage, however Globe Biotech head of analysis and improvement Asif Mahmud mentioned that they discovered constructive end result from the animal model trial.
Globe Biotech is in talks with ICDDR,B on conducting the medical trial of its vaccines within the nation, he mentioned.
Prime authorities officers mentioned that Bangladesh was in dialogue with a variety of corporations who had been growing COVID-19 vaccines.
It has just lately signed an settlement on procuring Oxford College’s Covid-19 vaccine.
Developed by AstraZeneca, the vaccine is awaiting approval earlier than it’s marketed.
On November 5 the federal government reached the tripartite contract with Serum Institute of India and native pharmaceutical firm Beximco to import three crore doses of the AstraZeneca COVID-19 vaccine.